🚀 VC round data is live in beta, check it out!
Biomaxima Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biomaxima and similar public comparables like Predilife, Synthetic MR, Immunovia, Genomed and more.
Biomaxima Overview
About Biomaxima
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
Founded
1997
HQ
Employees
116
Website
Financials (LTM)
EV
$18M
Biomaxima Financials
Biomaxima reported last 12-month revenue of $17M and EBITDA of $1M.
In the same LTM period, Biomaxima generated $1M in EBITDA and $112K in net income.
Revenue (LTM)
Biomaxima P&L
In the most recent fiscal year, Biomaxima reported revenue of $15M and EBITDA of $1M.
Biomaxima expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $17M | XXX | $15M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $6M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $1M | XXX | $1M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $112K | XXX | $149K | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biomaxima Stock Performance
Biomaxima has current market cap of $14M, and enterprise value of $18M.
Market Cap Evolution
Biomaxima's stock price is $3.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18M | $14M | 0.1% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiomaxima Valuation Multiples
Biomaxima trades at 1.1x EV/Revenue multiple, and 11.9x EV/EBITDA.
EV / Revenue (LTM)
Biomaxima Financial Valuation Multiples
As of April 20, 2026, Biomaxima has market cap of $14M and EV of $18M.
Equity research analysts estimate Biomaxima's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biomaxima has a P/E ratio of 121.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV (current) | $18M | XXX | $18M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.9x | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBIT | 39.5x | XXX | 57.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.7x | XXX | XXX | XXX |
| P/E | 121.1x | XXX | 90.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (26.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biomaxima Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biomaxima Margins & Growth Rates
Biomaxima's revenue in the last fiscal year grew by 14%.
Biomaxima's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Biomaxima Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 15% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biomaxima Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biomaxima | XXX | XXX | XXX | XXX | XXX | XXX |
| Predilife | XXX | XXX | XXX | XXX | XXX | XXX |
| Synthetic MR | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunovia | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosynex | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomaxima M&A Activity
Biomaxima acquired XXX companies to date.
Last acquisition by Biomaxima was on XXXXXXXX, XXXXX. Biomaxima acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biomaxima
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiomaxima Investment Activity
Biomaxima invested in XXX companies to date.
Biomaxima made its latest investment on XXXXXXXX, XXXXX. Biomaxima invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biomaxima
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biomaxima
| When was Biomaxima founded? | Biomaxima was founded in 1997. |
| Where is Biomaxima headquartered? | Biomaxima is headquartered in Poland. |
| How many employees does Biomaxima have? | As of today, Biomaxima has over 116 employees. |
| Is Biomaxima publicly listed? | Yes, Biomaxima is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Biomaxima? | Biomaxima trades under BMX ticker. |
| When did Biomaxima go public? | Biomaxima went public in 2010. |
| Who are competitors of Biomaxima? | Biomaxima main competitors are Predilife, Synthetic MR, Immunovia, Genomed. |
| What is the current market cap of Biomaxima? | Biomaxima's current market cap is $14M. |
| What is the current revenue of Biomaxima? | Biomaxima's last 12 months revenue is $17M. |
| What is the current revenue growth of Biomaxima? | Biomaxima revenue growth (vs. last FY) is 14%. |
| What is the current EV/Revenue multiple of Biomaxima? | Current revenue multiple of Biomaxima is 1.1x. |
| Is Biomaxima profitable? | Yes, Biomaxima is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biomaxima? | Biomaxima's last 12 months EBITDA is $1M. |
| What is Biomaxima's EBITDA margin? | Biomaxima's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Biomaxima? | Current EBITDA multiple of Biomaxima is 11.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.